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Background: Recent evidence suggests that aromatase may be involved in the pathogenesis of malignant
mesothelioma. Here, we evaluated the effect of exemestane, an inhibitor of aromatase, in the treatment of
mesothelioma using in vitro and in vivo preclinical models.
Results: We show a significant reduction of cell proliferation, survival, migration and block of cells in S phase of cell
cycle in mesothelioma cells upon exemestane treatment. Moreover, we find that CD44, which is involved in
mesothelioma cells migration, was modulated by exemestane via cAMP and pCREB. Most importantly, in mice
mesothelioma xenograft exemestane causes a significant decrease in tumor size and the association pemetrexed/
exemestane is more effective than pemetrexed/cisplatin.
Conclusion: The preclinical mesothelioma model suggests that exemestane might be beneficial in mesothelioma
treatment.
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Malignant Mesotheliomas (MM) are aggressive and lethal
neoplasms arising from mesothelial cells lining the pleura,
peritoneum, tunica vaginalis testis and pericardium.
Human malignant pleural mesothelioma (MPM) is the
most common form of mesothelioma that grows aggres-
sively, with dissemination throughout the pleural cavity,
and is frequently associated with massive pleural effu-
sion [1]. MPM is considered to be closely associated
with a personal history of prolonged exposure to asbes-
tos fibres in patients [2,3], although several etiologic
factors iron [4] and simian virus 40 (SV40) [5] are re-
ported to be involved in the development of MPM. The
incidence of MPM is expected to increase at an alarm-
ing rate over the next few years, despite the banning of* Correspondence: galati@ifo.it
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unless otherwise stated.asbestos. Disease incidence varies markedly within and
between countries. The highest annual rates of disease, ap-
proximately 30 case per million, are reported in Australia
and Great Britain. The risk of disease increases with age
and is higher in men. Time from asbestos exposure to
disease diagnosis is on average greater than 40 years. Non
occupational asbestos exposures contribute an increasing
proportion of disease. With the exception of the United
States, incidence continues to be on the increase. In devel-
oped countries peak incidence is expected to occur before
2030 [6,7]. MPM, sometimes takes 10 years or more for
changes to appear that are indicative of pleural disease,
and even longer for symptoms to manifest. Patients fre-
quently present respiratory symptoms, including dyspnea,
shortness of breath and chest pain, extremely limiting the
quality of life of the patients with this disease. Following
diagnosis, most cases of malignant mesothelioma have
poor survival [1]. The standard therapeutic modalities for
MPM, including surgery, chemotherapy and radiation,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ation of cisplatin and pemetrexed has become standard
first-line therapy worldwide for patients who are not suit-
able for aggressive surgery, or in whom chemotherapy is
recommended as part of a multimodality regimen with a
mean survival of 12.1 months and 18.34 [9-11]. Therefore,
in order to improve the clinical outcome in the pharma-
cological treatment of this refractory tumour, drugs aimed
at targeting novel and/or characterized tumour-specific
cellular targets are needed. The pathogenic mechanisms
underlying mesothelioma involve epigenetic gene regula-
tion [12] and deregulation of multiple signaling pathways,
including sonic hedgehog signalling [13,14], activation of
multiple receptor tyrosine kinases such as the epidermal
growth factor receptor (EGFR) family and MET, and sub-
sequent deregulations of mitogen-activated protein kinase
(MAPK) and phosphatidylinositol-3-kinase (PI3K)-AKT
signaling cascades, the TNF-α/NF-κB survival pathway,
Wnt signaling, and loss of tumor suppressors such as
Neurofibromatosis type 2, p16INK4A, and p14ARF [15,16].
Understanding the mechanisms of the dysregulated
signaling pathways allows strategies for development of
targeted new therapies against this devastating disease.
Recently, we have demonstrated the presence of aro-
matase (CYP19A1) in MPM cell lines and tumor tissue
sections from patients with MPM [17,18]. CYP19A1 was
expressed in the majority of MPM samples as a cytoplas-
mic protein and the cytoplasmic expression of CYP19A1
significantly correlated with poor survival [17]. The World
Health Organization classifies MM into epithelial, sarco-
matoid, and biphasic types, each of which can be subdi-
vided further. This classification has implications for both
diagnosis and prognosis [19]. Prognosis is poor for all
MMs, but sarcomatoid MMs have a particularly poor re-
sponse rate to treatment: a significant association between
high expression of CYP19A1 and sarcomatoid MPMs was
found [17]. These observations suggested that CYP19A1
plays a role in tumour progression in MPM. CYP19A1 is a
key enzyme in the biosynthesis of estrogen (converting
testosterone into estradiol (E2). Females were identified
as being a positive prognostic factor for peritoneal
MM: female patients have a median survival than males
(17.3 months compared to 11.8 months respectively)
[20,21]. The estrogen receptors expression using im-
munohistochemistry, was demonstrated in peritoneal
tumors and not in pleural tumors [22]. Recently, immu-
nohistochemical analysis revealed intense nuclear ERβ
staining in normal pleura that was reduced in MM tissues.
Conversely, neither MM nor normal pleura stained posi-
tive for ERα [23]. This leads to more carefully explore the
role of estrogen in the pathogenesis of MM and especially
on MPM.
Exemestane an inhibitor of CYP19A1 type 1 (steroidal
inactivator), induces cell death in Ist Mes1, Ist Mes2 andMPP89 MPM cell lines [17]. This initial finding has pro-
vided the impetus for the studies presented here, aimed
to investigate the mechanism of action of exemestane
on MPM cells and xenograft MPM models. We have
thus identified possible pathways between cyclic adenosine
monophosphate (cAMP), cAMP response element-binding
protein (CREB), CD44 and pAKT, Bcl-xL that are down-
regulated by exemestane in MPM cells sensitive. Finally,
we demonstrated that exemestane was effective in vivo
alone and in combination with pemetrexed, and that the
effect of this association was superior compared to the
therapeutic combination cisplatin/pemetrexed.
Results
Exemestane inhibits MPM cell growth in vitro
Exemestane was used to evaluate the impact of CYP19A1
blockade in our MPM preclinical models. Met-5A, MSTO
and NCI cells were treated with incremental drug doses
for 24 and 48 hours. Exemestane 35 and 70 μM induced a
significant (P < 0.05) dose-dependent decrease of meta-
bolic activity in MSTO (Figure 1A). Only with exemestane
70 μM at 48 h a significant (P = 0.0036) reduction of the
metabolic activity in NCI was observed (Figure 1A).
Exemestane 35 and 70 μM was no active in Met-5A
(Figure 1B). Exemestane had antiproliferative action dose
response dependent in MSTO (Figure 1C). For subsequent
experiments, in an attempt to find the cause of the differ-
ent levels of sensitivity to the drug between MSTO and
NCI, the concentration of 35 μM that is closest to 50% of
MSTO cell death and had no effect on NCI was chosen.
Exemestane 35 μM reduced the colony formation capacity
of MSTO whereas no difference compared to the control
was observed in NCI and Met-5A (Figure 1D). Next, the
effects of CYP19A1 inhibition on cell-cycle progression
and apoptosis were evaluated. Upon 24 h exemestane
treatment MSTO resulted in a cell cycle arrest in S-phase
(Figure 1E). This was transient, as we could not observe
48 h post-treatment, probably due to its half-life. In agree-
ment, increased levels of p21 and decreased Bcl-2 and
Bcl-xL (Figure 1F) were detected in western blot. The
effect of exemestane on MPM cell migration was evalu-
ated. In MSTO and other exemestane sensitive MPM cell
lines (Ist Mes1, Ist Mes2 and MPP89), the drug blocks
migration (Figure 1G). Altogether, these results suggest
that CYP19A1 blockade results in decreased MPM cell
proliferation, S cell-cycle arrest and abrogation of the
ability to migrate.
cAMP and CD44 are the targets of exemestane in MPM cell
We sought to identify the possible target of exemestane
in MPM cell lines. Reports in the literature on other
types of cancer cells indicate drug action on cAMP [24]
and the involvement of CD44 in the migration of MPM
cells [25]. As depicted in Figure 2A, MSTO, Ist-Mes1,
Figure 1 Exemestane acts on MPM cell growth, cell-cycle progression and migration. A, NCI was not very sensitive to exemestane (EXE),
only 70 μM of drug for 48 h had a significant response versus untreated (CNTR) cells; B, exemestane was not effective in Met-5A. Significant decrease
in MSTO cell growth was observed upon different exemestane dosage treatment as per XTT (A), manual cell counting (C) and clonogenicity assays
(35 μM exemestane) (D). E, exemestane (35 μM) induced cell cycle arrest in S-phase; F, Western blotting showed increase in p21 and decrease in Bcl-2
and Bcl-xL expression. G, reduced MPM cell lines sensitive migration in response to 35 μM exemestane treatment was identified by wound healing assay.
Cell migration was not inhibited in NCI. Graphs represent the average of at least 3 repeated experiments; *, statistically significant effects (P < 0.05).
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Figure 2 Exemestane acts in MPM cells by cAMP and CD44. A, cAMP ELISA detects a decrease in cAMP levels upon 35 μM exemestane
treatment for 30 min (EXE), compared to untreated (CNTR), in all lines except NCI. B, western blot identifies CREB phosphorylation (pCREB)
inhibition in cell lines responsive to exemestane treatment (E30) versus untreated (C30). C, flow cytometric characterizzazion of CD44 expression
in untreated and treated MPM cell lines. Data are presented as a count of positive cells and numerical value indicates CD44 mean fluorescence
intensity (MIF) of total cell population in the sample analyzed. Excluding NCI, all MPM cell lines show a reduction of MIF. D, siRNACD44 in MSTO
and NCI reduced MPM cell lines migration in wound healing assay E, siRNA CD44 transfection resulted in decreased cell viability in MSTO and NCI cell
lines compared to no CD44 siRNA. In addition, exemestane treatment further reduces the MSTO cell survival. No effect was observed in NCI. F, Western
blot shows the silencing of CD44 occurring in MSTO and NCI. Moreover, the effect of exemestane in MSTO resulted in a decreased phosphorylation of
AKT and CREB and in the reduction of Bcl-xL both in silenced cells that did not. No change was observed in NCI upon exemestane treatment both in
silenced cells that did not. Graphs represent the average of at least 3 repeated experiments; *, statistically significant effects (P < 0.05).
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ment exhibited decreased levels of cAMP levels, con-
trary to what happens to the NCI. This suggests that
exemestane acts by modulating cAMP levels.
Western blott analysis shown an involvement of pCREB
in drug action (Figure 2B) and a direct correlation be-
tween cAMP level and pCREB expression was observed.
No change in total CREB was detected. Based on what we
postulate, pCREB was activated by cAMP also in MPM.
FITC-CD44 analysis, by flow cytometry, shows a re-
duction of fluorescence only in cells sensitive to exemes-
tane thus indicating that CD44 as a possible target of the
drug (Figure 2C). To test this assumption, we silenced
CD44 in MSTO and NCI and then investigated the effect
on migration. The silencing of CD44 in MSTO and NCI
inhibited the wound healing confirming the role of CD44
in cell migration (2D). Figure 2E shows the mean relative
viabilities of MSTO and NCI cells treated for 24 h with or
without the CD44siRNA in the presence or absence of exe-
mestane. It is evident that the silencing of CD44 kills both
cell lines, consequently, we can deduce that CD44 was
essential in the cellular growth. Moreover, the siR-
NACD44 does not make MPM cell lines more sensitive
to the action of the drug. Thus, suggesting that in both
cell lines, the direct target of exemestane might be
some factor upstream of CD44 that in NCI was not a
target upon 35 μM exemestane treatment. MSTO and
NCI without and with CD44si RNA show the same pat-
tern of pCREB and pAKT (Figure 2F MSTO Lane1,3;
NCI Lane5,7) and total AKT and CREB (data not
show). Exemestane decreases pAKT, pCREB and Bcl-xL
in MSTO (Figure 2F Lane 2,4) and not total AKT and
CREB. In contrast, no change was observed in NCI
pointing out pAKT, pCREB and Bcl-xL as possible targets
of the drug (Figure 2F Lane 5,7).Figure 3 Exemestane alone and in association with pemetrexed block
of tumor volume measurements in mice treated (EXE) or not (CNTRL) with ex
measurements in mice upon cisplatin-pemetrexed (C-P) or exemestane-peme
value represents the average and standard deviation, P is the p value assessedExemestane inhibits MPM cell growth in vivo
We next sought to evaluate whether the antiproliferative
effect of exemestane can also be observed in vivo. Using a
MPM xenograft animal model resulting from the subcuta-
neous injection of MSTO cells, we compared the effect of
exemestane alone or in association with pemetrexed on
tumor growth in immunodeficient mice as compared to ad-
ministration of the control vehicle (physiological solution)
and cisplatinum pemetrexed respectively (Figure 3). We de-
cided not to include in the study groups of mice treated
with cisplatinum or pemetrexed alone because the purpose
was to assess whether the exemestane-pemetrexed combin-
ation was more effective than standard therapy.
Since exemestane is a drug implicated in estrogen syn-
thesis, we used in the in vivo experiments mixed sex
mice (5 male and 5 female) for each group of treatment.
The treatment with exemestane for 60 days induced a
significant reduction (p = 0.03) of tumor growth com-
pared to the control group in 40 days. During therapy
and for 40 days after the end of treatment the mice were
in good health and the tumor continued to decline sig-
nificantly (p = 1.2 × 10−5) until the complete healing of 9
out of 12 mice in 100 days (Figure 3A). The association
cisplatin-pemetrexed and exemestane-pemetrexed were
significantly effective versus CNTRL with a p value of
5.2 × 10−4 and 1.8 × 10−5 respectively already in 30 days
of treatment. At same time, the association exemestane-
pemetrexed was significantly (P = 3.3 × 10−4) more effect-
ive than cisplatin-pemetrexed (Figure 3B). 40 days after
the end of treatments, 3 mice treated with cisplatin-
pemetrexed were dead and only 1 showed a complete
reduction in the mass, while in mice treated with
exemestane-pemetrexed 1 was dead and 7 showed a
complete reduction of the mass. The deviation standard
in Figure 3, especially at 100 days time point is verys growth of MPM tumor xenografts. A, Graphs represent 100 days
emestane for 60 days. B, Graphs represent 100 days of tumor volume
trexed (E-P) treatment for 60 days versus non treated mice (CNTRL). Each
using 2-tailed Student’s test.
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which the tumor has disappeared and not. These data
support the use of exemestane in the care of MPM.
Discussion
The current study highlights the effect of exemestane
and its potential translation into the clinical setting for
the treatment of MPM. A recent study reported the
presence of CYP19A1 in cells and tissues of MPM and
the antiproliferative action of exemestane in Ist-Mes1,
Ist-Mes2 and MPP89 [17]. Normal mesothelium exhib-
ited a weak positivity for CYP19A1 and the human
pleuralmesothelial cell Met-5A does not express appre-
ciable levels of CYP19A1 by western blot. Met-5A was
not sensitive to exemestame treatment. In order to bet-
ter understand the mechanism of action of exemestane
in vitro and in vivo we studied other two MPM cell lines,
MSTO tumorigenic in mice and NCI. Exemestane 35 μM
was found to inhibit the growth of MSTO cells in vitro,
inducing arrested cell-cycle progression abrogated the
tumor cell migration and reduced the colony formation
capacity (Figure 1). On the contrary, nothing like what
was observed in NCI, therefore this line was defined cell
resistant to 35 μM of drug. In vitro experiments per-
formed on MPM sensitive cell lines (MSTO, Ist-Mes1,
Ist-Mes2 and MPP89) and NCI resistent cell lines upon
exemestane treatment have helped us to identify drug
targets. The exemestane dosage for all experiments was
of 35 μM. Although the selected concentrations seem to
be high, similar concentrations of an aromatase inhibi-
tor have also been used in previous studies for in vitro
experiments [24,26]. The dose of exemestane currently
used in clinical practice is 25 mg daily. Exemestane
exhibits an excellent safety profile in humans, having no
significant toxicity at doses up to 600 mg/day and it is
exceptionally well tolerated [27]. At clinically adminis-
tered doses, the plasma half-lives of exemestane was
27 hours [28]. Exemestane is an irreversible, steroidal
aromatase inactivator, structurally related to the natural
substrate androstenedione. It acts as a false substrate
for the aromatase enzyme and is processed to an inter-
mediate that binds irreversibly to the active site of the
enzyme causing its inactivation, an effect also known as
“suicide inhibition” [29].
Another possible mechanism includes changes in aro-
matase activity through a cAMP-dependent mechanism
[30]. A previous study reported an increase of cAMP
levels in lung cancer cell lines, 15 min after treatment of
cells with exemestane. This effect was reversed 30 min
after the application of exemestane [24]. MPM cell lines
sensitive upon 30 min exemestane treatment exhibited
decreased levels of cAMP levels. This difference could
be due to the different tissue types of origin. cAMP is a
ubiquitous second messenger. Many growth factors andhormones regulate cellular activity through second mes-
sengers which correspondingly induce multifunctional
protein kinases [31].
Activation of cAMP signaling involves binding of an
extracellular ligand to a GPCR which through G proteins
regulates one of several isoforms of adenylyl cyclase
(AC) leading to cAMP generation. Although other effec-
tors of cAMP have been identified, the most common
downstream effector system is cAMP-dependent protein
kinase (PKA). In its inactive state, the PKA holoenzyme
consists of two catalytic (C) subunits bound noncova-
lently to a regulatory (R) subunit dimmer [32]. Binding
of four cAMP molecules, two to each R subunit, leads to a
conformational change and dissociation into an R subunit
dimer with four cAMP molecules bound and two C
monomers [33]. The C subunits then become catalytically
active and phosphorylate serine and threonine residues on
specific substrate proteins [34]. When cAMP rises, the C
subunit released from the holoenzyme enters the nucleus
by passive diffusion where it regulates a number of cellular
processes, including motility, metabolism, neurotrans-
mitter release, and transcription by the reversible phos-
phorylation of key substrates [35]. cAMP regulates the
expression of specific genes by mediating the PKA-
dependent phosphorylation of the CREB transcription
factor in a 30-min period [31]. In MPM cell lines treated
with exemestane, we found a direct correlation between
levels of cAMP and expression of p-CREB. In particular
the lines sensitive to exemestane treatment showed
levels of cAMP and p-CREB decreased compared to
controls untreated while in the line NCI resistant cAMP
levels and p-CREB increased also in the presence of the
drug (Figure 2A, B).
Exemestane inhibits cell migration in MPM cell lines
sensitive to the agent. Data report CD44 responsible for
cell migration in MM [25,36]. CD44 is a type I trans-
membrane glycoprotein (85–200 kDa) and functions as
the major cellular adhesion molecule for hyaluronic acid, a
component of the extracellular matrix. CD44 is expressed
in most human cell types and is implicated in a wide
variety of physiological and pathological processes,
including lymphocyte homing and activation, cell migra-
tion, tumor cell growth, metastasis [37] and chemoresis-
tance [38]. Flow cytometry (Figure 2C) revealed that
MPM cell lines highly expressed CD44 and exemestane
treatment reduces its levels in all lines except in NCI.
The silencing of CD44 in MSTO and NCI confirms the
importance of CD44 in cell migration and suggests its
essential in the response to the drug, although the direct
target of exemestane might be a factor upstream of CD44
that in NCI gives it resistance. Given the involvement of
pAKT, Bcl-xL in Ist-Mes1, Ist-Mes2 and MPP89 drug
response [17], we decided to assay their expression and
p-CREB in CD44 silenced MSTO and NCI cells upon
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p-CREB, pAKT and Bcl-xL expression were reduced by
treatment with exemestane only in MSTO (silencied or
not) indicating once again that the phosphorilation of these
could be a target of the drug. Altogether, these data suggest
that exemestane, reducing the levels of estradiol, affects
cAMP and phosphoinositide 3-kinases (PI3K) pathway
(Figure 4). Estrogen acts via the regulation of transcrip-
tional processes, involving nuclear translocation and
binding on specific response elements, thus leading to
regulation of target gene expression. However, the ob-
servation of the effects induced by steroid hormones
that are too fast to be mediated by the activation of
RNA and proteins, has led to the identification of non-
transcriptional mechanisms of signal transduction through
steroid hormone receptors. These so-called “non-
genomic” effects involve steroid-induced modulation of
cytoplasmic or of cell membrane-bound regulatory pro-
teins. Relevant biological actions of steroids have been as-
sociated with this signaling in different tissues. Ubiquitary
regulatory cascades such as MAPK [39], the phospha-
tidylinositol 3-OH kinase (PI3K) and tyrosine kinases [40]
are modulated through non-transcriptional mechanisms
by steroid hormones. Steroid hormone modulation of cell
membrane-associated molecules such as ion channels and
G-protein-coupled receptors (GPCR) has been shown in
diverse tissues [41]. Lines of evidence suggest that the
estrogen-mediated activation of AC occurs independ-
ently of known ERs but rather requires GPR30 protein
[42]. Since the exemestane induces a modulation of cAMP
in short time (30 min) and considering that cAMP isFigure 4 Hypothesized mechanism of action of exemestane on
MPM cells. The GPCR receptor binds estrogen and cause estrogen-
mediated cAMP stimulation and PI3K cascade. PI3K phosphorylates
AKT (pAkt) which in turn regulates Bcl-xL, anti-apoptotic protein. cAMP
stimulates PKA, which in turn activates CREB that translocates into the
nucleus and acts as a transcription factor for CD44. The action of
exemestane is carried out by reducing the levels of estradiol, its
binding with GPCR and related downstream pathway.produced upon AC activation, we ignored the classical
estrogen receptors and focused on GPR30.
The GPR30 receptor binds estrogen and cause estrogen-
mediated AC stimulation and PI3K cascade. PI3K are
family of lipid kinases capable of phosphorylating the
3’OH of the inositol ring of phosphoinositides. They are
responsible for coordinating a diverse range of cell func-
tions including proliferation and cell survival. PI3K phos-
phorylates AKT (pAkt) which in turn regulates Bcl-xL,
anti-apoptotic protein. The AC catalyzes the formation
of cAMP which stimulates PKA which in turn activates
CREB (pCREB). pCREB translocates into the nucleus and
acts as a transcription factor for several genes including
CD44. PI3K and cAMP pathways inhibition by exemes-
tane causes pAKT, BclxL, pCREB and CD44 down-
regulation in MPM cell resulting in cell death. Intuitively,
it can be hypothesized that the action of exemestane is
achieved by reducing the levels of estradiol, its binding
with GPR30 and related downstream pathway (Figure 4).
Further studies are underway to validate the role of
GPR30 in MPM. Using a MPM xenograft animal model
resulting from the subcutaneous injection of MSTO
cells, we compared the effect of exemestane on tumor
growth in immunodeficient mice versus to control.
Therapy was initiated after tumor establishment. Mice in
both groups were followed for tumor size and toxicity.
Treatment with exemestane induced tumor growth delay
(Figure 3A) and decreased tumor mass completely in 70%
of males and 80% of females as compared with control.
Altogether, the impact of exemestane on MPM xenografts
mirrors the effects noted in cell culture. Previous work
shows the effectiveness of pemetrexed and cisplatin in
MPM cell lines. Studies with the MSTO-211H cell line
showed synergistic effects when pemetrexed was com-
bined concurrently with cisplatin [43-45]. Pemetrexed is
the first and only chemotherapy agent that has been
granted marketing approval for use in combination with
cisplatin for the treatment of chemonaive patients with
unresectable MPM. Although pemetrexed combined
with cisplatin showed a significant survival prolongation
compared with cisplatin alone, the difference was only
2.8 months [46]. It is therefore necessary to augment
the therapeutic effect of pemetrexed to further improve
the survival of MPM patients. Therefore, given the grow-
ing body of clinical evidence suggesting only minimal ef-
fects of monotherapy, we decided to test the association
exemestane-pemetrexed compared to standard combin-
ation cisplatin-pemetrexed in nude mice. Although the
two treatments are effective in reducing the tumor mass,
the association exemestane-pemetrexed was significantly
(P = 0.039) more effective than cisplatin-pemetrexed
(Figure 3B). In the present study, we clearly showed the
increased efficacy of exemestane alone or in combination
with pemetrexed versus the standard therapy pemetrexed-
Nuvoli et al. Molecular Cancer 2014, 13:69 Page 8 of 11
http://www.molecular-cancer.com/content/13/1/69cisplatinum against MPM in the xenograft implantation
model. In this context should not be underestimated
that exemestane was as effective as the combination
pemetrexed-exemestane, therefore exemestane mono-
therapy could be very beneficial to MPM patients.
We could not do a histologic examination to clarify
the mechanism of the increased efficacy of exemestane
and conventional chemotherapy because the therapy was
so effective that we could not obtain enough tumor sam-
ples. These findings are encouraging and possibly sup-
port further investigation of exemestane in the clinical
MPM context and highlight the opportunity to test, in
the experimental MPM model, new compounds active
with the same mechanism of action [47]. Exemestane is
widely used in the treatment of breast cancer. It is active
clinically in preventing, delaying progression of, and
treating mammary cancers, many of which are estrogen
receptor-positive. Exemestane 25 mg orally once daily
was generally well tolerated without major toxicity [48]
and it displays anti-inflammatory properties [49]. Given
that exemestane has already been approved, it may proceed
rapidly in clinical trials. After evaluating the benefits of
exemestane alone or in association with chemotherapy in a
group of patients, this therapy can be applied in MPM
treatment protocols. Exemestane could possibly open new
treatment strategies in association with standard therapy
for patients afflicted with MPM. At present there are no
clinical trials on the inhibitors of CYP19A1 in MPM,
this may be probably due to the recent identification of
CYP19A1 in MPM. In lung cancer, where studies of
CYP19A1 are at a more advanced stage, some clinical stud-
ies consider the inhibitors of CYP19A1 an anti-oestrogen.
Methods
Cell lines and reagents
The human pleural mesothelial cell Met-5A and the hu-
man pleural MPM cell lines MSTO-211H (MSTO) and
NCIH-2452 (NCI) were obtained from the American Type
Culture Collection (ATCC) (Rockville, Md) and Ist-Mes1,
Ist-Mes2, and MPP89 were obtained from Genova
Institute Culture Collection. Cell lines were cultured as
described previously [38]. Before treatment with exemes-
tane, all cell lines were gradually conditioned in DMEM/
F12 +Glutamax (Invitrogen) supplemented with 10% FBS
and antibiotics.
The cell proliferation kit II (XTT) was purchased from
Roche Molecular Biochemicals, Indianapolis, cAMP ELISA
Kit from R&D Systems, the siRNA CD44 (5′GAACG
AAUCCUGAAGACAU 3′, as 5′AUGUCUUCAGGAU
UCGUUC3′) from Sigma, lipofectamine 2000 from
Invitrogen, exemestane from Sequoia Research, Peme-
trexed (Alimta) from Eli Lilly & Co, Cisplatino from Pfizer
and Vitamina B12 (Dobetin) from Angelini SPA. Commer-
cially available antibodies were used for immunoblodetection of: Bcl-2, p21, pCreb and CD44 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), Bcl- ×L (Cell
Signaling Technology) and γ-tubulina (Sigma, Saint
Louis Missouri, USA).
Cellular growth assays
XTT assays: The in vitro drug sensitivity in MSTO and
NCI was assessed by Cell Proliferation kit (XTT), ac-
cording to the manufacturer’s instructions. The assay is
based on the cleavage of the yellow tetrazolium salt
XTT to form an orange formazan dye by metabolic ac-
tive cells. The drug was administered at doses and inter-
vals as indicated. Absorbance was measured at 492 nm
with a reference wavelength at 650 nm and the absorb-
ance values of treated cells are presented as a percentage
of the absorbance of dimethyl sulfoxide (DMSO) treated
cells (CNTRL). All experimental points were quantified
fivefold. Every single point was compared to their re-
spective control with the same amount of DMSO. The
anti-proliferative drug activity was assessed in a mono-
layer culture condition by plating cell lines in T25 flask.
After 24 h, vehicle (DMSO) and exemestane were added
at different concentrations for the time indicated in the
experiment. The expansion of culture cell proliferation
was quantified by manual cell counting. Experiments were
repeated in triplicate and media values were calculated.
Colony formation assay: five hundred viable cells per
well (treated with exemestane and CNTRL) were plated
and allowed to grow in normal medium for 10 (MSTO
and NCI) and14 (Met5A) days and then stained for
30 min at room temperature with a 6% glutaraldehyde,
0.5% crystal violet solution. Pictures were captured digit-
ally and colonies were counted. All experiments were re-
peated at a minimum twice for each cell line.
Wound healing assay
Cells (MSTO, NCI, Ist-Mes1, Ist-Mes2 and MPP89) grown
to 95% confluence were seeded in 6-well tissue culture
plates and wounded with a sterile 10-μL pipet tip to re-
move cells. Digital micrographs were taken after scratching
and at the indicated times.
Cyclic adenosine monophosphate (cAMP) assay
MPM cells (MSTO, NCI, Ist-Mes1, Ist-Mes2 and MPP89)
were seeded into a T25 flask with phenol-red free DMEM/
F12 for 24 h, then incubated in the presence or absence of
exemestane for 30 min. The cAMP amount in the lysate
was measured by ELISA according to the manufacturer’s
instructions. This assay is based on the competitive bind-
ing technique. A monoclonal antibody specific for cAMP
binds to the goat anti-mouse antibody coated onto the mi-
croplate. Following a wash to remove excess monoclonal
antibody, cAMP present in a sample competes with a
fixed amount of horseradish peroxidase (HRP)-labelled
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followed by another wash to remove excess conjugate and
unbound sample. A substrate solution is added to the
wells to determine the bound enzyme activity. The colour
development is stopped and the absorbance is read at
450 nm. The intensity of the colour is inversely propor-
tional to the concentration of cAMP in the sample.
Flow cytometry
Cell cycle analyses cells were fixed in 70% ethanol and
stored at −20°C over night. Fixed cells were treated with
1 mg/ml RNase A (cat. 12091021, Invitrogen) for 1 h at
37°C and DNA was stained with Propidium Iodide
(Sigma). Samples were acquired with a Guava EasyCyte
8HT flow cytometer (Millipore). Cell cycle distribution is
shown.
CD 44 analysis: The CD44 expression was evaluated by
flow cytometry on the MSTO, NCI, Ist-Mes1, Ist-Mes2
and MPP89 MPM cell lines utilizing a FACSCanto flow
cytometer (BD Biosciences, Franklin Lakes, NJ, USA)
equipped with FACSDiva v6.1.3 data acquisition and
analysis software (BD, San Jose, CA). Ten microL of the
CD44-Fitc (BD Pharmingen) McAb was utilised to
evaluate the percentage and mean intensity of fluores-
cence (MIF) of the MPM cell lines before and 24 hours
after exemestane treatment. MPM single cell suspen-
sion was washed with phosphate buffered saline (PBS)
pH 7.2–7.4, then spun at 1.500 rpm for 10 minutes,
supernatant decanted, and incubated with the directly
conjugated CD44 McAb utilizing the BD FACS Lyse
and Wash Assistant according to the Duo-Lyse program
(BD Biosciences, San Jose, CA, USA). Data was col-
lected until the end of the aliquot was achieved. Data is
presented as counts of positive cells and CD44 mean
fluorescence intensity of total cell population in the
sample analyzed.
CD44 short interfering RNA (siRNA)
siRNA oligonucleotide targeting CD44 was transfected
into MPM cells using lipofectamine 2000 following the
manufacturer’s instructions using 200 nmol siRNA per
10 cm dish. Cells were incubated with siRNA for 5 hours
and then left for 48 hours to achieve knockdown of
CD44 protein as measured by immunoblot. Control cells
were transfected with a scrambled siRNA oligonucleotide
at matching concentration. Cells were then treated with
vehicle or exemestane for 30 min and 24 hours and
assayed for CD44, pCREB, pAKT and Bcl-xL by western
blot.
Western blot analysis
Briefly, 25–50 μg of proteins extracted as described pre-
viously [50] from cultured cells were separated by SDS-
PAGE and transferred onto nitrocellulose membranes.Membranes were blocked and blotted with relevant anti-
bodies. Horseradish peroxidase–conjugated secondary
antibodies were detected by Enhanced ChemiLumines-
cence (ECL Amersham Biosciences). Goat anti mouse or
rabbit IgG horseradish peroxidaseconjugated secondary
antibodies (1:3.000) (Bio-Rad Laboratories; Hercules,
CA, USA) were used.
In vivo animal models
Female and male nude mice (6–8 weeks old; weight 18–
25 g) were obtained from Charles River. Mice were housed
in the animal facility of the Regina Elena National Cancer
Institute for 2 weeks before each experiment; animals had
ad libitum water and food. The Ethics Committee of the
Cancer Institute approved all the experimental protocols
that were carried out in accordance with Italian regulations
and with the Guide for the Care and Use of Laboratory
Animals. A mouse xenograft model of mesothelioma
was created as described previously [51]. MSTO cell sus-
pensions (2.5 × 106) in 0,2 ml of complete medium were
injected subcutaneously into the flank of CD1 nude mice
(n = 12 (7 males and 5 females)/treatment group) and
growth was measured twice weekly with calipers and cal-
culated by the formula: 4/3 π (large diameter) × (small
diameter)2. After the establishment of palpable lesions
(average diameter >5 mm), mice were assigned to one of
the following treatment groups: 1) Control, 2) Exemestane
(8.25 mg/Kg, intraperitoneal (i.p.) 5 days a week). After
testing the efficacy of exemestane alone, MSTO cell sus-
pensions were injected subcutaneously into the flank of
CD1 nude mice (n = 10 (5 males and 5 females)/treatment
group) and mice were assigned to one of the following
treatment groups 3) Cisplatin (3 mg/Kg i.p. once every
21 days) and Pemetrexed (150 mg/Kg i.p once every
21 days), 4) Exemestane (8.25 mg/Kg, i.p. 5 days a week)
and Pemetrexed (150 mg/Kg i.p once every 21 days). A
week before starting treatment in groups 3 and 4 an intra-
muscular dose of Vitamin B12 0.58 mg/kg was given. We
chose the dose and the schedule of treatment by simulat-
ing those used in humans. Experimental groups were
treated for 60 days. Mice were followed for tumor size,
well being, and body weight and sacrificed 100 days after
the start of treatment.
Statistics
Cell culture–based assays were repeated at least 3 times;
mean ± SD was calculated. Cell lines were examined
separately. Differences in xenograft tumor size in vivo
were assessed using a 2-tailed Student’s t test. Signifi-
cance was set at P < 0.05.
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